6GFI
| Structure of Human Mesotrypsin in complex with APPI variant T11V/M17R/I18F/F34V | Descriptor: | 1,2-ETHANEDIOL, Amyloid-beta A4 protein, PRSS3 protein | Authors: | Shahar, A, Cohen, I, Radisky, E, Papo, N, Naftaly, S. | Deposit date: | 2018-04-30 | Release date: | 2018-09-12 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (2.3 Å) | Cite: | Mapping protein selectivity landscapes using multi-target selective screening and next-generation sequencing of combinatorial libraries. Nat Commun, 9, 2018
|
|
6BX8
| Human Mesotrypsin (PRSS3) Complexed with Tissue Factor Pathway Inhibitor Variant (TFPI1-KD1-K15R-I17C-I34C) | Descriptor: | SULFATE ION, Tissue factor pathway inhibitor, Trypsin-3 | Authors: | Coban, M, Sankaran, B, Cohen, I, Hockla, A, Papo, N, Radisky, E.S. | Deposit date: | 2017-12-18 | Release date: | 2019-02-06 | Last modified: | 2024-10-30 | Method: | X-RAY DIFFRACTION (1.98 Å) | Cite: | Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin. J. Biol. Chem., 294, 2019
|
|
6HAR
| Crystal structure of Mesotrypsin in complex with APPI-M17C/I18F/F34C | Descriptor: | 1,2-ETHANEDIOL, Amyloid-beta A4 protein, CALCIUM ION, ... | Authors: | Shahar, A, Cohen, I, Radisky, E, Papo, N. | Deposit date: | 2018-08-08 | Release date: | 2019-02-06 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (1.497 Å) | Cite: | Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin. J.Biol.Chem., 294, 2019
|
|
6XXN
| Crystal structure of NB7, a nanobody targeting prostate specific membrane antigen | Descriptor: | NB_7_a,b,c,f, NB_7_g, NB_7_h, ... | Authors: | Shahar, A, Rosenfeld, L, Papo, N. | Deposit date: | 2020-01-28 | Release date: | 2020-06-10 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (2.65 Å) | Cite: | Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer. J.Med.Chem., 63, 2020
|
|
6XXO
| |
6XXP
| |
5NX1
| Combinatorial Engineering of Proteolytically Resistant APPI Variants that Selectively Inhibit Human Kallikrein 6 for Cancer Therapy | Descriptor: | Amyloid-beta A4 protein, Kallikrein-6 | Authors: | Shahar, A, Sananes, A, Radisky, E.S, Papo, N. | Deposit date: | 2017-05-09 | Release date: | 2018-05-30 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (1.853 Å) | Cite: | A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering. J.Biol.Chem., 293, 2018
|
|
5NX3
| Combinatorial Engineering of Proteolytically Resistant APPI Variants that Selectively Inhibit Human Kallikrein 6 for Cancer Therapy | Descriptor: | Amyloid-beta A4 protein, Kallikrein-6 | Authors: | Shahar, A, Sananes, A, Radisky, E.S, Papo, N. | Deposit date: | 2017-05-09 | Release date: | 2018-05-30 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (2.296 Å) | Cite: | A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering. J.Biol.Chem., 293, 2018
|
|
5LXF
| Crystal structure of the human Macrophage Colony Stimulating Factor M- CSF_C31S variant | Descriptor: | Macrophage colony-stimulating factor 1 | Authors: | Shahar, A, Papo, N, Zarivach, R, Kosloff, M, Bakhman, A, Rosenfeld, L, Zur, Y, Levaot, N. | Deposit date: | 2016-09-21 | Release date: | 2017-07-12 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Engineering a monomeric variant of macrophage colony-stimulating factor (M-CSF) that antagonizes the c-FMS receptor. Biochem. J., 474, 2017
|
|